Department of Food Science & Nutrition, Woosuk University, Wanju, 55338, Republic of Korea.
Healthcare Claims & Management Inc, Jeonju, 54858, Republic of Korea.
BMC Complement Med Ther. 2023 Oct 19;23(1):368. doi: 10.1186/s12906-023-04206-2.
This trial aimed to evaluate the anti-obesity effects and safety of Neoagaro-oligosaccharides (NAOs) in humans in a 16 week, randomized, double-blind, placebo-controlled clinical trial.
One hundred overweight or obese subjects with a body mass index of 23 to 34.9 kg/m and a percent body fat of > 25% for males or > 30% for females were enrolled. NAOs or placebo products were administered at 3 g (twice a day, four capsules once) each for 16 weeks. Efficacy and safety biomarkers were measured before and after intervention.
After 16 weeks of intervention, the group administered with NAOs had statistically significant decreases in visceral fat area and visceral-subcutaneous fat area ratio compared to the placebo group. The NAOs group suppressed the increase in weight and BMI compared to the placebo group, which was significant between groups. High-density lipoprotein- cholesterol was increased in the group administered with NAOs, which showed a significant trend compared to the placebo group. Clinical changes were not observed for any safety biomarkers.
These results suggest that NAOs have a beneficial effect on obesity. Thus, NAOs could be used as an anti-obesity supplement without side effects.
cris.nih.go.kr: (KCT0006640, 07/10/2021).
本试验旨在评估 Neoagaro-oligosaccharides（NAOs）在人体中的抗肥胖作用和安全性，为期 16 周，采用随机、双盲、安慰剂对照临床试验。
共招募 100 名超重或肥胖者，体重指数为 23 至 34.9 kg/m²，男性体脂率>25%，女性体脂率>30%。NAOs 或安慰剂产品以 3g（每天两次，每次四粒）的剂量给药，共 16 周。在干预前后测量疗效和安全性生物标志物。
干预 16 周后，与安慰剂组相比，NAOs 组的内脏脂肪面积和内脏-皮下脂肪面积比有统计学意义的降低。与安慰剂组相比，NAOs 组抑制了体重和 BMI 的增加，两组之间存在显著差异。NAOs 组的高密度脂蛋白胆固醇增加，与安慰剂组相比呈显著趋势。任何安全性生物标志物均未观察到临床变化。
这些结果表明，NAOs 对肥胖具有有益的作用。因此，NAOs 可作为一种无副作用的抗肥胖补充剂使用。
cris.nih.go.kr（KCT0006640，2021 年 7 月 10 日）。
